Sanctuary Advisors LLC Has $1.63 Million Stock Position in argenx SE (NASDAQ:ARGX)

Sanctuary Advisors LLC grew its position in argenx SE (NASDAQ:ARGX) by 18.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,441 shares of the company’s stock after acquiring an additional 377 shares during the quarter. Sanctuary Advisors LLC’s holdings in argenx were worth $1,625,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Nkcfo LLC bought a new position in argenx in the fourth quarter worth $68,000. Advisors Preferred LLC acquired a new position in shares of argenx in the 4th quarter valued at $73,000. GAMMA Investing LLC lifted its holdings in shares of argenx by 44.8% during the 4th quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock worth $155,000 after acquiring an additional 78 shares during the period. Keudell Morrison Wealth Management acquired a new stake in shares of argenx during the 3rd quarter valued at about $207,000. Finally, SG Americas Securities LLC increased its stake in argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after acquiring an additional 21 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. JPMorgan Chase & Co. raised their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and set a $717.00 target price (up previously from $670.00) on shares of argenx in a research report on Tuesday, January 14th. Oppenheimer reiterated an “outperform” rating and issued a $675.00 price target (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. Deutsche Bank Aktiengesellschaft cut argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. Finally, Wells Fargo & Company boosted their target price on shares of argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Stock Performance

NASDAQ ARGX opened at $626.13 on Tuesday. The stock has a market capitalization of $38.04 billion, a P/E ratio of -711.51 and a beta of 0.58. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21. The stock has a fifty day moving average of $642.93 and a 200-day moving average of $588.61.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.